EMPULSE
a Phase III trial to evaluate the effect on changes in NT-proBNP, safety and tolerability of once daily oral EMPaglilozin 10 mg compared to placebo, initiated in patients hospitalized for acUte decompensated heart faiLure who have been StabilizEd (EMPULSE)
- Stage
- klaar
- Medicine
- Empagliflozine
- Population
- Hartfalen
- Phase
- III
- First Patient In
- 1 June 2020
- Last Patient In
- 18 February 2021
- Last Patient Last Visit
- 2 June 2021
National Lead
